On Thursday, Wolfe Research made a significant adjustment to its rating for Danaher Corporation (NYSE:DHR), upgrading the stock from Peer Perform to Outperform. Accompanying this upgrade, the firm also set a price target of $285.00 for the science and technology innovator.
The decision came after a notable decline in Danaher's share price, which dropped by more than 10% over the past week. Despite this decrease, Wolfe Research maintains a positive outlook on the company's fundamentals. According to the firm, the current business environment for Danaher remains robust and is expected to support growth.
Looking ahead, Wolfe Research's model predicts approximately 6% core top-line growth and around 29% operating margin for Danaher by 2025. These projections suggest earnings per share (EPS) could reach $8.25. The firm believes its model captures a conservative estimate for the company's performance in 2025.
Wolfe Research anticipates that Danaher's shares will experience a degree of multiple expansion over the next 12 months. Additionally, the firm expects upward revisions to consensus EBITDA (earnings before interest, taxes, depreciation, and amortization) and EPS estimates for the fiscal year 2025. These two factors are projected to propel Danaher's stock to meet or exceed the $285 price target and to perform better than its industry peers.
In other recent news, Danaher Corporation has been the subject of several adjustments from financial analysts. KeyBanc Capital Markets raised its price target from $290 to $310, maintaining an Overweight rating, following earnings that surpassed expectations. KeyBanc cited Danaher's strong position in bioprocessing and biotechnology research, which accounts for approximately 40% of its revenue, as a key factor.
Meanwhile, TD Cowen updated the company's price target to $315 from the previous $310, reiterating a Buy rating. This adjustment followed Danaher's third-quarter performance, which surpassed expectations, yet resulted in a 4% drop in stock value.
Baird trimmed its price target for Danaher to $277 from $278 but retained an Outperform rating, following Danaher's third-quarter results, which exceeded expectations due to strong performance in the Biotechnology segment and an increase in Cepheid respiratory products.
Leerink Partners reduced their price target for Danaher to $275 from $280, while sustaining an Outperform rating. The firm highlighted Danaher's leadership in the bioprocess tools market, despite concerns about the impact of China's macroeconomic conditions and the recovery of instrumentation sales.
Lastly, Danaher reported steady third-quarter results with revenues of $5.8 billion and adjusted diluted net earnings per share of $1.71, mirroring the previous year's performance. The company maintained its full-year guidance, expecting a low single-digit decline in core revenue and projecting an adjusted operating profit margin of approximately 29% for 2024. These are the recent developments for Danaher Corporation.
InvestingPro Insights
To complement Wolfe Research's optimistic outlook on Danaher Corporation (NYSE:DHR), recent data from InvestingPro offers additional context. Despite the recent share price decline, InvestingPro Tips highlight that Danaher has maintained dividend payments for an impressive 32 consecutive years, demonstrating long-term financial stability. This consistency aligns with Wolfe Research's positive view on the company's fundamentals.
Furthermore, InvestingPro data reveals that Danaher operates with a moderate level of debt, and its cash flows can sufficiently cover interest payments. These factors support the company's financial health and its ability to invest in growth initiatives, which could contribute to the projected 6% core top-line growth mentioned by Wolfe Research.
It's worth noting that while Wolfe Research expects multiple expansion, InvestingPro Tips indicate that Danaher is currently trading at high earnings and EBIT valuation multiples. This information suggests that investors should carefully consider the company's valuation in light of its growth prospects.
For investors seeking a more comprehensive analysis, InvestingPro offers 16 additional tips on Danaher, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.